Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity

Kazuhiro Sase^{1

2}, Mikio Mukai³, Yasuhiro Fujiwara^{4

5}

Affiliations

¹ Clinical Pharmacology and Regulatory Science, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
² Institute for Medical Regulatory Science, Organization for University Research Initiatives, Waseda University, Tokyo, Japan.
³ Department of Medical Check-up, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka, Japan.
⁴ Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

PMID: 36875908
PMCID: PMC9982292
DOI: 10.1016/j.jaccao.2022.11.001

Editorial

Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity

Kazuhiro Sase et al. JACC CardioOncol. 2022.

. 2022 Dec 6;5(1):145-148.

doi: 10.1016/j.jaccao.2022.11.001. eCollection 2023 Feb.

Authors

Kazuhiro Sase^{1

2}, Mikio Mukai³, Yasuhiro Fujiwara^{4

5}

Affiliations

¹ Clinical Pharmacology and Regulatory Science, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
² Institute for Medical Regulatory Science, Organization for University Research Initiatives, Waseda University, Tokyo, Japan.
³ Department of Medical Check-up, Osaka International Cancer Institute, Osaka Prefectural Hospital Organization, Osaka, Japan.
⁴ Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
⁵ Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.

PMID: 36875908
PMCID: PMC9982292
DOI: 10.1016/j.jaccao.2022.11.001

No abstract available

Keywords: European Society of Cardiology; cardio-oncology; cardiovascular disease; clinical practice guidelines.

PubMed Disclaimer

Conflict of interest statement

This study was supported in part by a Japan Society for the Promotion of Science/Ministry of Education, Culture, Sports, Science and Technology (KAKENHI 18K12134 and 20K08427); the Ministry of Health, Labour and Welfare (20FA1018 and 20KC2009); and the Agency for Medical Research and Development (20ck0106633h0001) for Dr. Sase. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Cited by

Association Between Amount of Physical Activity and Clinical Outcomes After Treatment for Cardiovascular Disease in Cancer Survivors.
Nozaki K, Hamazaki N, Kamiya K, Ueno K, Miki T, Nanri Y, Ogura K, Uchida S, Maekawa E, Nabeta T, Iida Y, Yamaoka-Tojo M, Matsunaga A, Sasaki J, Ako J. Nozaki K, et al. Circ Rep. 2024 Nov 14;6(12):547-554. doi: 10.1253/circrep.CR-24-0105. eCollection 2024 Dec 10. Circ Rep. 2024. PMID: 39659630 Free PMC article.
Breaking the One-Size-Fits-All Approach in Cardio-Oncology: Applying the BEST to Optimize Cardiotoxicity Monitoring.
Ohtsu H, Shimomura A, Sase K. Ohtsu H, et al. JACC CardioOncol. 2025 Jun;7(4):442-444. doi: 10.1016/j.jaccao.2025.05.007. JACC CardioOncol. 2025. PMID: 40537193 Free PMC article.
Real-world data of cardio-oncologic interventions for cardiovascular adverse events with oral oncolytics.
Abboud K, Umoru G, Trachtenberg B, Ajewole V. Abboud K, et al. Cardiooncology. 2024 Apr 9;10(1):22. doi: 10.1186/s40959-024-00221-5. Cardiooncology. 2024. PMID: 38594785 Free PMC article.

References

1. Institute of Medicine . National Academies Press; 2011. Clinical Practice Guidelines We Can Trust. - DOI - PubMed
1. Lyon A.R., Lopez-Fernandez T., Couch L.S., et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Eur Heart J. 2022;43(41):4229–4361. - PubMed
1. Zamorano J.L., Lancellotti P., Rodriguez Munoz D., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;37(36):2768–2801. - PubMed
1. Shelburne N., Simonds N.I., Adhikari B., et al. Changing hearts and minds: improving outcomes in cancer treatment-related cardiotoxicity. Curr Oncol Rep. 2019;21(1):9. - PubMed
1. Levis B.E., Binkley P.F., Shapiro C.L. Cardiotoxic effects of anthracycline-based therapy: what is the evidence, and what are the potential harms? Lancet Oncol. 2017;18(8):e445–e456. - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity

Affiliations

Clinical Practice Guidelines in Cardio-Oncology: A Sea of Opportunity

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources